The clinical- and cost-effectiveness of lenalidomide for multiple myeloma in people who have received at least one prior therapy: an evidence review of the submission from Celgene

Martin Hoyle; Gabriel Rogers; Ruth Garside; Tiffany Moxham; Ken Stein

The clinical- and cost-effectiveness of lenalidomide for multiple myeloma in people who have received at least one prior therapy: an evidence review of the submission from Celgene

Martin Hoyle, Gabriel Rogers, Ruth Garside, Tiffany Moxham, Ken Stein

Research output: Book/Report › Commissioned report

Original language	English
Publisher	University of Exeter
Commissioning body	The National Institute for Health and Care Excellence (NICE)
Number of pages	124
Publication status	Published - 2008
Externally published	Yes

Access to Document

https://www.nice.org.uk/guidance/ta171/documents/multiple-myeloma-lenalidomide-evidence-review-group-report2

Cite this

Hoyle, M., Rogers, G., Garside, R., Moxham, T., & Stein, K. (2008). The clinical- and cost-effectiveness of lenalidomide for multiple myeloma in people who have received at least one prior therapy: an evidence review of the submission from Celgene. University of Exeter. https://www.nice.org.uk/guidance/ta171/documents/multiple-myeloma-lenalidomide-evidence-review-group-report2

@book{e56a649c5ade4a1792fd6ece2a3cbcac,

title = "The clinical- and cost-effectiveness of lenalidomide for multiple myeloma in people who have received at least one prior therapy: an evidence review of the submission from Celgene",

author = "Martin Hoyle and Gabriel Rogers and Ruth Garside and Tiffany Moxham and Ken Stein",

year = "2008",

language = "English",

publisher = "University of Exeter",

}

Hoyle, M, Rogers, G, Garside, R, Moxham, T & Stein, K 2008, The clinical- and cost-effectiveness of lenalidomide for multiple myeloma in people who have received at least one prior therapy: an evidence review of the submission from Celgene. University of Exeter. <https://www.nice.org.uk/guidance/ta171/documents/multiple-myeloma-lenalidomide-evidence-review-group-report2>

TY - BOOK

T1 - The clinical- and cost-effectiveness of lenalidomide for multiple myeloma in people who have received at least one prior therapy

T2 - an evidence review of the submission from Celgene

AU - Hoyle, Martin

AU - Rogers, Gabriel

AU - Garside, Ruth

AU - Moxham, Tiffany

AU - Stein, Ken

PY - 2008

Y1 - 2008

UR - https://www.nice.org.uk/guidance/ta171

M3 - Commissioned report

BT - The clinical- and cost-effectiveness of lenalidomide for multiple myeloma in people who have received at least one prior therapy

PB - University of Exeter

ER -

The clinical- and cost-effectiveness of lenalidomide for multiple myeloma in people who have received at least one prior therapy: an evidence review of the submission from Celgene

Access to Document

Other files and links

Cite this